The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%, till 2030{Roots Analysis}
Roots Analysis has done a detailedstudy on “MicrobialContract Biomanufacturing Market,2020-2030” covering key aspectsof the industry and identifying potential future growth opportunities.
To order this 320+ page report, which features 150+ figuresand 150+ tables, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
Key Market Insights
§ Over 115 companies,across the world, claim to offer a variety of product development,manufacturing and support services, for various types of biologics that aremanufactured / expressed in microbial systems
§ Majority of theplayers have the necessary infrastructure / capability to produce different biologics,primarily proteins, at all scales using bacterial / yeast expression vectors
§ The market featuresthe presence of several well-established players across the globe; the US, theUK and Germany emerged as current hubs for production of biologics usingmicrobial strains
§ Several serviceproviders, involved in this domain, are steadily expanding their capabilitiesin order to enhance their respective service portfolio and maintain acompetitive edge in the industry
§ The growth trend of outsourcingmicrobial manufacturing operations is evident from the rise in recentpartnership activity, as well as expansion initiatives undertaken by CMOs tomeet the growing demand for novel biologics
§ Big pharma playershave also made significant investments in this domain through establishment ofnew facilities, entering into strategic collaborations and undertakingfinancial investments
§ Future growth of themarket is likely to be driven by increased adoption of novel biologics that areproduced via microbial systems; we expect the service-based revenues to grow ata CAGR of over 8%
§ In the long term, theprojected opportunity for contract biomanufacturing is anticipated to bedistributed across contract service providers of different sizes, scales ofmanufacturing and key geographical regions
For more information,please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVESUMMARY
3. INTRODUCTION
3.1 Chapter Overview
3.2. Overview of Biopharmaceuticals
3.3. Expression Systems Used for Biopharmaceutical Production
3.3.1. Microbial Expression Systems
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Fungal Expression Systems
3.3.1.3. Yeast Expression Systems
3.3.2. Mammalian versus Microbial Expression Systems
3.4. Microbial Manufacturing Process
3.4.1. Cell Banking
3.4.2. Upstream Processing
3.4.3. Fermentation
3.4.4. Downstream Processing
3.5. Overview of Contract Manufacturing
3.6. Need for Outsourcing Microbial Biomanufacturing Operations
3.7. Commonly Outsourced Microbial Biomanufacturing Operations
3.8. Advantages and Risks Associated with Outsourcing MicrobialBiomanufacturing Operations
3.9. Key Considerations while Selecting a CMO Partner
3.10. Concluding Remarks
4. MARKETLANDSCAPE
4.1. Chapter Overview
4.2. Microbial Contract Biomanufacturing Market: Overall MarketLandscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Manufacturing Facility
4.2.5. Analysis by Scale of Operation
4.2.6. Analysis by Type of Biologic
4.2.7. Analysis by Type of Expression System Used
4.2.8. Analysis by Type of Fermenter
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Regulatory Accreditations / Certifications
4.3. Regional Analysis
4.3.1. Analysis by North America
4.3.2. Analysis by Europe
4.3.3. Analysis by Asia Pacific
4.3.4. Analysis by Middle East and North Africa
5. COMPANY COMPETITIVENESSANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Competitiveness Analysis
5.4.1. Competitiveness Analysis: Companies in North America
5.4.2. Competitiveness Analysis: Companies in Europe
5.4.3. Competitiveness Analysis: Companies in Asia Pacific
6. COMPANYPROFILES
6.1. Chapter Overview
6.2. Microbial Contract Biomanufacturers based in North America
6.2.1. AGC Biologics
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Manufacturing Capabilities and Facilities
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Aldevron
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Manufacturing Capabilities and Facilities
6.2.2.4. Recent Developments and Future Outlook
6.2.3. BioVectra
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Manufacturing Capabilities and Facilities
6.2.3.4. Recent Developments and Future Outlook
6.2.4. Ology Bioservices
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Manufacturing Capabilities and Facilities
6.2.4.4. Recent Developments and Future Outlook
6.3. Microbial Contract Biomanufacturers Based in Europe
6.3.1. Eurogentec
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Manufacturing Capabilities and Facilities
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Northway Biotechpharma
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Manufacturing Capabilities and Facilities
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Porton Biopharma
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Manufacturing Capabilities and Facilities
6.3.3.4. Recent Developments and Future Outlook
6.4. Microbial Contract Biomanufacturers Based in Asia Pacific
6.4.1. EirGenix
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Manufacturing Capabilities and Facilities
6.4.1.4. Recent Developments and Future Outlook
6.4.2. Etinpro
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Manufacturing Capabilities and Facilities
6.4.2.4. Recent Developments and Future Outlook
6.4.3. Stelis Biopharma
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Capabilities and Facilities
6.4.3.4. Recent Developments and Future Outlook
7. RECENTPARTNERSHIPS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Microbial Contract Biomanufacturers: Recent Partnerships
7.3.1. Analysis by Year of Partnerships
7.3.2. Analysis by Type of Partnership Model
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Type of Biologic
7.3.5. Analysis by Focus Area
7.3.6. Analysis by Target Therapeutic Area
7.3.7. Analysis by Region
7.3.7.1. Country-Wise Distribution
7.3.7.2. Intercontinental and Intracontinental Agreements
7.3.8. Most Active Players: Analysis by Number of Partnerships
7.4. Microbial Contract Biomanufacturers: Mergers and Acquisitions
7.4.1. Analysis by Year of Merger / Acquisition
7.4.2. Analysis by Type of Acquisition
7.4.3. Regional Analysis
7.4.3.1. Continent-wiseDistribution
7.4.3.2. Country-wiseDistribution
7.4.3.3. Intercontinental andIntracontinental Deals
7.4.4. Most Active Players: Analysis by Number of Acquisitions
7.4.5. Analysis by Key Value Drivers
7.4.5.1. Analysis by Year of Acquisition and Key Value Drivers
8. RECENTEXPANSIONS
8.1. Chapter Overview
8.2. Microbial Contract Biomanufacturers: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Scale of Operation
8.2.4. Analysis by Type of Biologic
8.3. Geographical Analysis
8.3.1. Continent-wise Distribution
9. MICROBIALFERMENTATION TECHNOLOGY PLATFORMS
9.1. Chapter Overview
9.2. Technology Platforms Commonly Used for Microbial Fermentation
9.3. Upcoming Platforms-General Technologies
10. ATTRACTIVENESSCOMPETITION MATRIX
10.1. Chapter Overview
10.2. AC Matrix: An Overview
10.2.1. Strong Business Segment
10.2.2. Average Business Segment
10.2.3. Weak Business Segment
10.3. AC Matrix: Analytical Methodology
10.4. AC Matrix: Analyzing the Data for North America
10.5. AC Matrix: Analyzing the Data for Europe
10.6. AC Matrix: Analyzing the Data for Asia Pacific and Middle East
11. MAKE VERSUSBUY DECISION MAKING FRAMEWORK
11.1. Chapter Overview
11.2. Assumptions and Parameter Definitions
11.2.1. Scenario 1
11.2.2. Scenario 2
11.2.3. Scenario 3
11.2.4. Scenario 4
11.3. Concluding Remarks
12. BIG PHARMAINITITATIVES IN MICROBIAL BIOMANUFACTURING
12.1. Chapter Overview
12.2. List of Microbial Biopharmaceutical Manufacturing Initiatives ofBig Pharma Players
12.2.1. Analysis by Number of Initiatives
12.2.2. Analysis by Year of Initiative
12.2.3. Analysis by Company and Year of Initiative
12.2.4. Analysis by Purpose of Initiative
12.2.5. Analysis by Company and Purpose of Initiative
12.2.6. Analysis by Type of Initiative
12.2.7. Analysis by Scale of Operation
12.2.8. Analysis by Type of Drug Molecule
12.2.9. Analysis by Type of Microbial Expression System Used
12.2.10. Geographical Analysis byInvestment Made
12.3. Competitive Benchmarking of Big Pharmaceutical Players
12.3.1. Big Pharma Summary
13. CASE STUDY:COMPARISON OF SMALL MOLECULE AND LARGE MOLECULEDRUGS / THERAPIES
13.1. Chapter Overview
13.2. Small Molecule and Large Molecule Drugs / Therapies
13.2.1. Comparison of Key Characteristics
13.2.2. Comparison of Microbial Manufacturing Process
13.2.2.1. Microbial ContractManufacturers Providing Services for Small Molecules
13.2.3. Comparison of Key Manufacturing-related Challenges
14. MARKETSIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Forecast Methodology
14.3. Overall Microbial Contract Biomanufacturing Market, 2020-2030
14.3.1. Microbial Contract Biomanufacturing Market for APIs, 2020-2030
14.3.2. Microbial Contract Biomanufacturing Market for FDFs, 2020-2030
14.4. Microbial ContractBiomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Biologic
14.5. Microbial Contract BiomanufacturingMarket, 2020, 2025 and 2030: Distribution by Type of Microbial ExpressionSystem Used
14.6. Microbial ContractBiomanufacturing Market, 2020, 2025 and 2030: Distribution by Scale ofOperation
14.7. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030:Distribution by Type of End User
14.8. Microbial ContractBiomanufacturing Market, 2020, 2025, 2030: Distribution by Key GeographicalRegions
14.8.1. Microbial ContractBiomanufacturing Market in North America, 2020-2030
14.8.1.1. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Proteins
14.8.1.2. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Enzymes
14.8.1.3. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Growth Hormones
14.8.1.4. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Antibody-based Drugs
14.8.1.5. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Other Biologics
14.8.1.6. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.1.7. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Yeast Cell-based Expression Systems
14.8.1.8. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.1.9. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Commercial Operations
14.8.1.10. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Preclinical / Clinical Operations
14.8.1.11. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Small Companies
14.8.1.12. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Mid-sized Companies
14.8.1.13. Microbial Contract Biomanufacturing Market in North America,2020-2030: Share of Large / Very Large Companies
14.8.2. Microbial ContractBiomanufacturing Market in Europe, 2020-2030
14.8.2.1. Microbial ContractBiomanufacturing Market in Europe, 2020-2030: Share of Proteins
14.8.2.2. Microbial ContractBiomanufacturing Market in Europe, 2020-2030: Share of Enzymes
14.8.2.3. Microbial ContractBiomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones
14.8.2.4. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Antibody-based Drugs
14.8.2.5. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Other Biologics
14.8.2.6. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.2.7. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Yeast Cell-based Expression Systems
14.8.2.8. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.2.9. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Commercial Operations
14.8.2.10. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Preclinical / Clinical Operations
14.8.2.11. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Small Companies
14.8.2.12. Microbial Contract Biomanufacturing Market in Europe,2020-2030: Share of Mid-sized Companies
14.8.2.13. Microbial Contract Biomanufacturing Market in Europe, 2020-2030:Share of Large / Very Large Companies
14.8.3. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030
14.8.3.1. Microbial ContractBiomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract BiomanufacturingMarket in Asia Pacific, 2020-2030: Share of Enzymes
14.8.3.3. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Growth Hormones
14.8.3.4. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Antibody- based Drugs
14.8.3.5. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Yeast Cell-basedExpression Systems
14.8.3.8. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.9. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Commercial Operations
14.8.3.10. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Preclinical / Clinical Operations
14.8.3.11. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Small Companies
14.8.3.12. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Mid-sized Companies
14.8.3.13. Microbial Contract Biomanufacturing Market in Asia Pacific,2020-2030: Share of Large / Very Large Companies
14.8.4. Microbial Contract Biomanufacturing Market in Middle East and NorthAfrica, 2020-2030
14.8.4.1. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Proteins
14.8.4.2. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Shareof Enzymes
14.8.4.3. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Shareof Growth Hormones
14.8.4.4. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Shareof Antibody-based Drugs
14.8.4.5. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Shareof Other Biologics
14.8.4.6. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Shareof Bacterial Cell-based Expression Systems
14.8.4.7. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.4.8. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.4.9. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Commercial Operations
14.8.4.10. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Preclinical / Clinical Operations
14.8.4.11. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share of Small Companies
14.8.4.12. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share ofMid-sized Companies
14.8.4.13. Microbial Contract Biomanufacturing Market in Middle East andNorth Africa, 2020-2030: Share ofLarge / Very Large Companies
14.8.5. Microbial Contract Biomanufacturing Market in Latin America,2020-2030
15. IMPACT OF COVID-19 PANDEMIC ON MICROBIALCONTRACT BIOMANUFACTURING MARKET
15.1. Chapter Overview
15.2. Current Options and Recuperative Initiatives of Key Players
15.2.1. KBI Biopharma
15.2.2. Lonza
15.2.3. Porton Pharma Solutions
15.2.4. Wacker Biotech
15.2.5. Wuxi AppTec
15.3. Impact on Microbial ContractBiomanufacturing Market Opportunity
15.4. Recuperative Strategies for CMO Businesses
15.4.1. Strategies for Implementation in the Short /Mid Term
15.4.2. Strategies for Implementation in the LongTerm
16. SWOTANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
17. CONCLUDINGREMARKS
17.1. Chapter Overview
18. INTERVIEWTRANSCRIPTS
18.1. Chapter Overview
18.2. Meteoric Biopharmaceuticals
18.2.1. Company Snapshot
18.2.2. Interview Transcript:Gaurav Kaushik, Managing Director and Chief Executive Officer (Q4 2019)
18.3. List Biological Laboratories
18.3.1. Company Snapshot
18.3.2. Interview Transcript:Debbie Pinkston, Vice President, Sales and Business Development (Q3 2019)
18.4. OLON
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Andrea Conforto, Sales andMarketing-Bioservices Director)
18.5. Luina Bio
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Max Rossetto, General Manager-BusinessDevelopment
18.6. WACKER Biotech
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Rob van Dijk, Business Development Manager(Q4 2019)
19. APPENDIX 1:TABULATED DATA
20. APPENDIX 2:LIST OF COMPANIES AND ORGANISTIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
